|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M and Bray F: Cancer incidence and mortality
worldwide: Sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer. 136:E359–E386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Markowitz SD and Bertagnolli MM: Molecular
basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carethers JM and Jung BH: Genetics and
genetic biomarkers in sporadic colorectal cancer. Gastroenterology.
149:1177–1190.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Issa JP: CpG island methylator phenotype
in cancer. Nat Rev Cancer. 4:988–993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kondo Y and Issa JPJ: Epigenetic changes
in colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iacopetta B, Grieu F, Li W, Ruszkiewicz A,
Caruso M, Moore J and Kawakami K: APC gene methylation is
inversely correlated with features of the CpG island methylator
phenotype in colorectal cancer. Int J Cancer. 119:2272–2278. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Derks S, Postma C, Moerkerk P, van den
Bosch SM, Carvalho B, Hermsen MA, Giaretti W, Herman JG, Weijenberg
MP, de Bruïne AP, et al: Promoter methylation precedes chromosomal
alterations in colorectal cancer development. Cell Oncol.
28:247–257. 2006.PubMed/NCBI
|
|
11
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman
JG, Baylin SB and Issa JPJ: CpG island methylator phenotype in
colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knudsen ES and Wang JY: Targeting the
RB-pathway in cancer therapy. Clin Cancer Res. 16:1094–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munro S, Carr SM and La Thangue NB:
Diversity within the pRb pathway: Is there a code of conduct?
Oncogene. 31:4343–4352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engelmann D and Pützer BM: The dark side
of E2F1: In transit beyond apoptosis. Cancer Res. 72:571–575. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Witkiewicz AK, Knudsen KE, Dicker AP and
Knudsen ES: The meaning of p16ink4a expression in
tumors: Functional significance, clinical associations and future
developments. Cell Cycle. 10:2497–2503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Knudsen KE, Diehl JA, Haiman CA and
Knudsen ES: Cyclin D1: Polymorphism, aberrant splicing and cancer
risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caca K, Feisthammel J, Klee K, Tannapfel
A, Witzigmann H, Wittekind C, Mössner J and Berr F: Inactivation of
the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct
cancers and bile tract cancer cell lines. Int J Cancer. 97:481–488.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toyooka S, Mitsudomi T, Soh J, Aokage K,
Yamane M, Oto T, Kiura K and Miyoshi S: Molecular oncology of lung
cancer. Gen Thorac Cardiovasc Surg. 59:527–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong SM, Park JY, Hruban RH and Goggins M:
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med.
135:716–727. 2011.PubMed/NCBI
|
|
20
|
Mori T, Miura K, Aoki T, Nishihira T, Mori
S and Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I
(multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor)
gene in esophageal squamous cell carcinoma. Cancer Res.
54:3396–3397. 1994.PubMed/NCBI
|
|
21
|
He J, Mokhtari K, Sanson M, Marie Y, Kujas
M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, et al:
Glioblastomas with an oligodendroglial component: A pathological
and molecular study. J Neuropathol Exp Neurol. 60:863–871. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maesawa C, Tamura G, Nishizuka S,
Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K and
Satodate R: Inactivation of the CDKN2 gene by homozygous
deletion and de novo methylation is associated with advanced stage
esophageal squamous cell carcinoma. Cancer Res. 56:3875–3878.
1996.PubMed/NCBI
|
|
23
|
Oshima M, Okano K, Muraki S, Haba R, Maeba
T, Suzuki Y and Yachida S: Immunohistochemically detected
expression of 3 major genes (CDKN2A/p16TP53, and
SMAD4/DPC4) strongly predicts survival in patients with
resectable pancreatic cancer. Ann Surg. 258:336–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ueki T, Hsing AW, Gao YT, Wang BS, Shen
MC, Cheng J, Deng J, Fraumeni JF Jr and Rashid A: Alterations of
p16 and prognosis in biliary tract cancers from a population-based
study in China. Clin Cancer Res. 10:1717–1725. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Taga S, Osaki T, Ohgami A, Imoto H,
Yoshimatsu T, Yoshino I, Yano K, Nakanishi R, Ichiyoshi Y and
Yasumoto K: Prognostic value of the immunohistochemical detection
of p16INK4 expression in nonsmall cell lung carcinoma. Cancer.
80:389–395. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herman JG, Merlo A, Mao L, Lapidus RG,
Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of
the CDKN2/p16/MTS1 gene is frequently associated with
aberrant DNA methylation in all common human cancers. Cancer Res.
55:4525–4530. 1995.PubMed/NCBI
|
|
27
|
Guan RJ, Fu Y, Holt PR and Pardee AB:
Association of K-ras mutations with p16 methylation in human colon
cancer. Gastroenterology. 116:1063–1071. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burri N, Shaw P, Bouzourene H, Sordat I,
Sordat B, Gillet M, Schorderet D, Bosman FT and Chaubert P:
Methylation silencing and mutations of the p14ARF and p16INK4a
genes in colon cancer. Lab Invest. 81:217–229. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yi J, Wang ZW, Cang H, Chen YY, Zhao R, Yu
BM and Tang XM: p16 gene methylation in colorectal cancers
associated with Duke's staging. World J Gastroenterol. 7:722–725.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esteller M, González S, Risques RA,
Marcuello E, Mangues R, Germà JR, Herman JG, Capellà G and Peinado
MA: K-rasp16 aberrations confer poor prognosis in human
colorectal cancer. J Clin Oncol. 19:299–304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim BN, Yamamoto H, Ikeda K, Damdinsuren
B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, et al:
Methylation and expression of p16INK4 tumor suppressor
gene in primary colorectal cancer tissues. Int J Oncol.
26:1217–1226. 2005.PubMed/NCBI
|
|
32
|
Shima K, Nosho K, Baba Y, Cantor M,
Meyerhardt JA, Giovannucci EL, Fuchs CS and Ogino S: Prognostic
significance of CDKN2A (p16) promoter methylation and loss of
expression in 902 colorectal cancers: Cohort study and literature
review. Int J Cancer. 128:1080–1094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maeda K, Kawakami K, Ishida Y, Ishiguro K,
Omura K and Watanabe G: Hypermethylation of the CDKN2A gene in
colorectal cancer is associated with shorter survival. Oncol Rep.
10:935–938. 2003.PubMed/NCBI
|
|
34
|
Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J
and Chen M: The prognostic value of CDKN2A hypermethylation
in colorectal cancer: A meta-analysis. Br J Cancer. 108:2542–2548.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; Oxford: 2009
|
|
36
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eads CA, Danenberg KD, Kawakami K, Saltz
LB, Blake C, Shibata D and Laird PW: MethyLight: A high-throughput
assay to measure DNA methylation. Nucleic Acids Res. 28:E322001.
View Article : Google Scholar
|
|
38
|
Eads CA, Lord RV, Wickramasinghe K, Long
TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester
TR, Skinner KA, et al: Epigenetic patterns in the progression of
esophageal adenocarcinoma. Cancer Res. 61:3410–3418.
2001.PubMed/NCBI
|
|
39
|
Ogino S, Kawasaki T, Brahmandam M, Cantor
M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ,
Laird PW, Loda M, et al: Precision and performance characteristics
of bisulfite conversion and real-time PCR (MethyLight) for
quantitative DNA methylation analysis. J Mol Diagn. 8:209–217.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ogino S, Cantor M, Kawasaki T, Brahmandam
M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M and
Fuchs CS: CpG island methylator phenotype (CIMP) of colorectal
cancer is best characterised by quantitative DNA methylation
analysis and prospective cohort studies. Gut. 55:1000–1006. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mitomi H, Fukui N, Tanaka N, Kanazawa H,
Saito T, Matsuoka T and Yao T: Aberrant p16INK4a
methylation is a frequent event in colorectal cancers: Prognostic
value and relation to mRNA expression and immunoreactivity. J
Cancer Res Clin Oncol. 136:323–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li J, Poi MJ and Tsai MD: The regulatory
mechanisms of tumor suppressor P16INK4A and relevance to
cancer. Biochemistry. 50:5566–5582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Veganzones-de-Castro S, Rafael-Fernández
S, Vidaurreta-Lázaro M, de-la-Orden V, Mediero-Valeros B, Fernández
C and Maestro-de las Casas ML: p16 gene methylation in colorectal
cancer patients with long-term follow-up. Rev Esp Enferm Dig.
104:111–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tada T, Watanabe T, Kazama S, Kanazawa T,
Hata K, Komuro Y and Nagawa H: Reduced p16 expression correlates
with lymphatic invasion in colorectal cancers.
Hepatogastroenterology. 50:1756–1760. 2002.
|
|
47
|
Rayess H, Wang MB and Srivatsan ES:
Cellular senescence and tumor suppressor gene p16. Int J Cancer.
130:1715–1725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Serrano M, Gómez-Lahoz E, DePinho RA,
Beach D and Bar-Sagi D: Inhibition of ras-induced proliferation and
cellular transformation by p16INK4. Science. 267:249–252. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dai CY, Furth EE, Mick R, Koh J, Takayama
T, Niitsu Y and Enders GH: p16 INK4a expression begins early in
human colon neoplasia and correlates inversely with markers of cell
proliferation. Gastroenterology. 119:929–942. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Palmqvist R, Rutegård JN, Bozoky B,
Landberg G and Stenling R: Human colorectal cancers with an intact
p16/cyclin D1/pRb pathway have up-regulated p16 expression and
decreased proliferation in small invasive tumor clusters. Am J
Pathol. 157:1947–1953. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhao P, Hu YC and Talbot IC: Expressing
patterns of p16 and CDK4 correlated to prognosis in colorectal
carcinoma. World J Gastroenterol. 9:2202–2206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dublin EA, Patel NK, Gillett CE, Smith P,
Peters G and Barnes DM: Retinoblastoma and p16 proteins in mammary
carcinoma: Their relationship to cyclin D1 and histopathological
parameters. Int J Cancer. 79:71–75. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hui R, Macmillan RD, Kenny FS, Musgrove
EA, Blamey RW, Nicholson RI, Robertson JF and Sutherland RL:
INK4a gene expression and methylation in primary breast
cancer: Overexpression of p16INK4a messenger RNA is a
marker of poor prognosis. Clin Cancer Res. 6:2777–2787.
2000.PubMed/NCBI
|
|
55
|
Quinn DI, Henshall SM and Sutherland RL:
Molecular markers of prostate cancer outcome. Eur J Cancer.
41:858–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Parry D, Bates S, Mann DJ and Peters G:
Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with
high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J.
14:503–511. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Knudsen ES and Knudsen KE: Tailoring to
RB: Tumour suppressor status and therapeutic response. Nat Rev
Cancer. 8:714–724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Craig C, Kim M, Ohri E, Wersto R, Katayose
D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P, et al: Effects
of adenovirus-mediated p16INK4A expression on cell cycle
arrest are determined by endogenous p16 and Rb status in human
cancer cells. Oncogene. 16:265–272. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Khleif SN, DeGregori J, Yee CL, Otterson
GA, Kaye FJ, Nevins JR and Howley PM: Inhibition of cyclin
D-CDK4/CDK6 activity is associated with an E2F-mediated induction
of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA.
93:4350–4354. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yao J, Pollock RE, Lang A, Tan M, Pisters
PW, Goodrich D, El-Naggar A and Yu D: Infrequent mutation of the
p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in
human primary soft-tissue sarcoma. Clin Cancer Res. 4:1065–1070.
1998.PubMed/NCBI
|
